No Cover Image

Journal article 617 views 63 downloads

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer

Pete Arnold Orcid Logo, Maria Cristina Penaloza-Ramos, Lola Adedokun, Sarah Rees, Mohamed Lockhat, Lisa Spary, Alan Watkins Orcid Logo, Vincent Gnanapragasam, Simon J. Crabb

Scientific Reports, Volume: 11, Issue: 1, Start page: 22151

Swansea University Authors: Pete Arnold Orcid Logo, Sarah Rees, Alan Watkins Orcid Logo

  • 41598_2021_Article_1042.pdf

    PDF | Version of Record

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

    Download (2.48MB)

Check full text

DOI (Published version): 10.1038/s41598-021-01042-7

Abstract

This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patien...

Full description

Published in: Scientific Reports
ISSN: 2045-2322
Published: Springer Science and Business Media LLC 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa58658
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2021-11-15T10:45:15Z
last_indexed 2021-12-01T04:18:38Z
id cronfa58658
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-11-30T16:27:38.2155900</datestamp><bib-version>v2</bib-version><id>58658</id><entry>2021-11-15</entry><title>Clinical characteristics and outcomes for patients with non&#x2011;metastatic castration-resistant prostate cancer</title><swanseaauthors><author><sid>fe5550ac567c45169564ddcb0dd83021</sid><ORCID>0000-0002-0017-5084</ORCID><firstname>Pete</firstname><surname>Arnold</surname><name>Pete Arnold</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>96c64d30e07b92b9bc0569160ae219a9</sid><firstname>Sarah</firstname><surname>Rees</surname><name>Sarah Rees</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>81fc05c9333d9df41b041157437bcc2f</sid><ORCID>0000-0003-3804-1943</ORCID><firstname>Alan</firstname><surname>Watkins</surname><name>Alan Watkins</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-11-15</date><deptcode>HDAT</deptcode><abstract>This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000&#x2013;2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91&#x2013;3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67&#x2013;3.09). Shorter PSA doubling time (&#x2264; 10 months, versus &gt; 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92&#x2013;2.30] versus 5.22 years [95% CI 4.87&#x2013;5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments.</abstract><type>Journal Article</type><journal>Scientific Reports</journal><volume>11</volume><journalNumber>1</journalNumber><paginationStart>22151</paginationStart><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2045-2322</issnElectronic><keywords/><publishedDay>12</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-11-12</publishedDate><doi>10.1038/s41598-021-01042-7</doi><url/><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Janssen-Cilag Ltd</funders><lastEdited>2021-11-30T16:27:38.2155900</lastEdited><Created>2021-11-15T10:41:06.4063407</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Pete</firstname><surname>Arnold</surname><orcid>0000-0002-0017-5084</orcid><order>1</order></author><author><firstname>Maria Cristina</firstname><surname>Penaloza-Ramos</surname><order>2</order></author><author><firstname>Lola</firstname><surname>Adedokun</surname><order>3</order></author><author><firstname>Sarah</firstname><surname>Rees</surname><order>4</order></author><author><firstname>Mohamed</firstname><surname>Lockhat</surname><order>5</order></author><author><firstname>Lisa</firstname><surname>Spary</surname><order>6</order></author><author><firstname>Alan</firstname><surname>Watkins</surname><orcid>0000-0003-3804-1943</orcid><order>7</order></author><author><firstname>Vincent</firstname><surname>Gnanapragasam</surname><order>8</order></author><author><firstname>Simon J.</firstname><surname>Crabb</surname><order>9</order></author></authors><documents><document><filename>58658__21527__3be2f88e2314486b851ac360397eb0ba.pdf</filename><originalFilename>41598_2021_Article_1042.pdf</originalFilename><uploaded>2021-11-15T10:41:06.4059776</uploaded><type>Output</type><contentLength>2598722</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2021-11-30T16:27:38.2155900 v2 58658 2021-11-15 Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer fe5550ac567c45169564ddcb0dd83021 0000-0002-0017-5084 Pete Arnold Pete Arnold true false 96c64d30e07b92b9bc0569160ae219a9 Sarah Rees Sarah Rees true false 81fc05c9333d9df41b041157437bcc2f 0000-0003-3804-1943 Alan Watkins Alan Watkins true false 2021-11-15 HDAT This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000–2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments. Journal Article Scientific Reports 11 1 22151 Springer Science and Business Media LLC 2045-2322 12 11 2021 2021-11-12 10.1038/s41598-021-01042-7 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University Janssen-Cilag Ltd 2021-11-30T16:27:38.2155900 2021-11-15T10:41:06.4063407 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Pete Arnold 0000-0002-0017-5084 1 Maria Cristina Penaloza-Ramos 2 Lola Adedokun 3 Sarah Rees 4 Mohamed Lockhat 5 Lisa Spary 6 Alan Watkins 0000-0003-3804-1943 7 Vincent Gnanapragasam 8 Simon J. Crabb 9 58658__21527__3be2f88e2314486b851ac360397eb0ba.pdf 41598_2021_Article_1042.pdf 2021-11-15T10:41:06.4059776 Output 2598722 application/pdf Version of Record true Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. true eng http://creativecommons.org/licenses/by/4.0/
title Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
spellingShingle Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
Pete Arnold
Sarah Rees
Alan Watkins
title_short Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_full Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_fullStr Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_full_unstemmed Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_sort Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
author_id_str_mv fe5550ac567c45169564ddcb0dd83021
96c64d30e07b92b9bc0569160ae219a9
81fc05c9333d9df41b041157437bcc2f
author_id_fullname_str_mv fe5550ac567c45169564ddcb0dd83021_***_Pete Arnold
96c64d30e07b92b9bc0569160ae219a9_***_Sarah Rees
81fc05c9333d9df41b041157437bcc2f_***_Alan Watkins
author Pete Arnold
Sarah Rees
Alan Watkins
author2 Pete Arnold
Maria Cristina Penaloza-Ramos
Lola Adedokun
Sarah Rees
Mohamed Lockhat
Lisa Spary
Alan Watkins
Vincent Gnanapragasam
Simon J. Crabb
format Journal article
container_title Scientific Reports
container_volume 11
container_issue 1
container_start_page 22151
publishDate 2021
institution Swansea University
issn 2045-2322
doi_str_mv 10.1038/s41598-021-01042-7
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000–2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments.
published_date 2021-11-12T04:15:21Z
_version_ 1763754032798629888
score 11.016235

Similar Items